Postmenopausal hormone therapy in the 21st century: Reconciling findings from observational studies and randomized clinical trials

Menopause

Volumn , Issue , 2007, Pages 619-626

  Michels, Karin B ^a   Manson, Joann E ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84882844704     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-012369443-0/50056-9     Document Type: Chapter

References (39)

1. Michels KB, Manson JE Postmenopausal hormone therapy: a reversal of fortune. Circulation 2003, 107:1830-1833.
2. Michels KB Hormone replacement therapy in epidemiologic studies and randomized clinical trials-are we checkmate?. Epidemiology 2003, 14:3-5.
3. Grodstein F, Clarkson TB, Manson JE Understanding the divergent data on postmenopausal hormone therapy. N Engl J Med 2003, 348:645-650.
4. Wilson R Feminine forever 1966, J.B.Lippincott Company, New York.
5. Beral V, Bull D, Reeves G Endometrial cancer and hormone-replacement therapy in the million women study. Lancet 2005, 365:1543-1551.
6. Chae C, Manson J Postmenopausal hormone therapy 2004, 349-363. Saunders/Elsevier, Philadelphia.
7. Kanaya AM, Herrington D, Vittinghoff E, et al. Glycemic effects of postmenopausal hormone therapy: the heart and estrogen/progestin replacement study. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1903, 138:1-9.
8. Chiantera V, Sarti CD, Fornaro F, et al. Long-term effects of oral and transdermal hormone replacement therapy on plasma homocysteine levels. Menopause 2003, 10:286-291.
9. Wakatsuki A, Ikenoue N, Shinohara K, Watanabe K, Fukaya T Different effects of oral and transdermal estrogen replacement therapy on matrix metalloproteinase and their inhibitor in postmenopausal women. Arterioscler Thromb Vase Biol 2003, 3:1948-1949.
10. Grodstein F, Stampfer MJ The epidemiology of postmenopausal hormone therapy and cardiovascular disease 2002, 67-78. Marcel Dekker, New York.
11. Grodstein F, Manson JE, Colditz GA, et al. A prospective, observational study of postmenopausal hormone therapy and primary prevention of cardiovascular disease. Ann Intern Med 2000, 133:933-941.
12. Grodstein F, Manson JE, Stampfer MJ Postmenopausal hormone use and secondary prevention of coronary events in the nurses' health study. A prospective, observational study. Ann Intern Med 2001, 135:1-8.
13. Grady D, Herrington D, Bittner V, et al. Cardiovascular disease outcomes during 6.8 years of hormone therapy: heart and estrogen Jprogestin replacement study follow-up (HERS II). JAMA 2002, 288:49-57.
14. Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in post-menopausal women. Heart and estrogen/progestin replacem (HERS) research group. JAMA 1998, 280:605-613.
15. Herrington DM, Reboussin DM, Brosnihan KB, et al. Effects of estrogen replacement on the progression of coronary-artery atherosclerosis. N Engl J Med 2000, 343:522-529.
16. Hodis HN, Mack WJ, Azen SP, et al. Hormone therapy and the progression of coronary-artery atherosclerosis in postmenopausal women. N Engl J Med 2003, 349:535-545.
17. Clarke SC, Kelleher J, Lloyd-Jones H, Slack M, Schofiel PM A study of hormone replacement therapy in postmenopausal women with ischaemic heart disease: the Papworth HRT atherosclerosis study. Br J Obstet Gynaecol 2002, 109:1056-1062.
18. Waters DD, Alderman EL, Hsia J, et al. Effects of hormone replacement therapy and antioxidant vitamin supplements on coronary atherosclerosis in postmenopausal women: a randomized controlled trial. JAMA 2002, 288:2432-2440.
19. Cherry N, Gilmour K, Hannaford P, et al. Oestrogen therapy for prevention of reinfarction in postmenopausal women: a randomised placebo controlled trial. Lancet 2002, 360:2001-2008.
20. Hemminki E, McPherson K Impact of postmenopausal hormone therapy on cardiovascular events and cancer: pooled data from clinical trials. BMJ 1997, 15:149-153.
21. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the women's health initiative randomized controlled tria. JAMA 2002, 288:321-333.
22. Manson JE, Hsia J, Johnson KC, et al. Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med 2003, 349:523-534.
23. Anderson GL, Limacher M, Assaf AR, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the women's health initiative randomized controlled trial. JAMA 2004, 291:1701-1712.
24. Wassertheil-Smoller S, Hendrix SL, Limacher M, et al. Effect of estrogen plus progestin on stroke in postmenopausal women: the women's health initiative. A randomized trial. JAMA 2003, 289:2673-2684.
25. Hendrix SL, Wassertheil-Smoller S, Johnson KC, et al. Effects of conjugated equine estrogen on stroke in the Women's Health Initiative. Circulation 2006, 113:2425-2434.
26. Smith NL, Heckbert SR, Lemaitre RN, et al. Esterified estrogens and conjugated equine estrogens and the risk of venous thrombosis. JAMA 2004, 292:1581-1587.
27. Cushman M, Kuller LH, Prentice R, et al. Estrogen plus progestin and risk of venous thrombosis. JAMA 2004, 292:1573-1580.
28. Colditz GA, Hankinson SE, Hunter DJ, et al. The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. N Engl J Med 1995, 332:1589-1593.
29. Schairer C, Lubin J, Troisi R, et al. Menopausal estrogen and estrogenprogestin replacement therapy and breast cancer risk. JAMA 2000, 283:485-491.
30. Grodstein F, Newcomb PA, Stampfer MJ Postmenopausal hormone therapy and the risk of colorectal cancer: a review and meta-analysis. Am J Med 1999, 106:574-582.
31. Matthews KA, Kuller LH, Wing RR, et al. Prior to use of estrogen replacement therapy, are users healthier than nonusers?. Am J Epidemiol 1996, 143:971-978.
32. Mikkola TS, Clarkson TB Estrogen replacement therapy, atherosclerosis, and vascular function. Cardiovasc Res 2002, 53:605-619.
33. Hodis HN, Mack WJ, Lobo RA, et al. Estrogen in the prevention of atherosclerosis. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 2001, 135:939-953.
34. Hsia J, Langer RD, Manson JE, et al. Conjugated equine estrogens and coronary heart disease. The Women's Health Initiative. Arch Intern Med 2006, 166:357-365.
35. Speizer FE Risks of postmenopausal hormone replacement. JAMA 2002, 288:2819-2820. author reply 2823-2814.
36. Radford N, Church T Risks of postmenopausal hormone replacement. JAMA 2002, 288:2819. author reply 2823-2814.
37. Grodstein F, Manson JE, Stampfer MJ Hormone therapy and coronary heart disease: the role of time since menopause and age at hormone initiation. J Women's Health 2006, 15:35-44.
38. Salpeter SR, Walsh JME, Greyber E, et al. Coronary heart disease events associated with hormone therapy in younger and older women. J Gen Intern Med 2006, 21:363-366.
39. Harman SM, Brinton EA, Cedars M, et al. KEEPS: The Kronos Early Estrogen Prevention Study. Climacteric 2005, 8:3-12.